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SUMMARY 
The study objective was to determine whether the ‘cardiac decompensation 
score’ could identify cardiac decompensation in a patient with existing cardiac 
compromise managed with intraaortic balloon counterpulsation (IABP). A one-
group, posttest-only design was utilised to collect observations in 2003 from 
IABP recipients treated in the intensive care unit of a 450 bed Australian, 
government funded, public, cardiothoracic, tertiary referral hospital. Twenty 
three consecutive IABP recipients were enrolled – four of whom died in ICU 
(17.4%). All non-survivors exhibited primarily rising scores over the 
observation period (p<0.001) and had final scores of 25 or higher. In contrast, 
the maximum score obtained by a survivor at any time was 15. Regardless of 
survival, scores for the 23 participants were generally decreasing immediately 
following therapy escalation (p=0.016). Further reflecting these changes in 
patient support, there was also a trend for scores to move from rising to falling 
at such treatment escalations (p=0.024). This pilot study indicates the ‘cardiac 
decompensation score’ to accurately represent changes in heart function 
specific to an individual patient. Use of the score in conjunction with IABP may 
lead to earlier identification of changes occurring in a patient’s cardiac function 
and thus facilitate improved IABP outcomes.  
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INTRODUCTION 
Withdrawal of intraaortic balloon counterpulsation (IABP) support, while 
progressive, is reliant on the degree of cardiac recovery. Presently, thorough 
knowledge, continual assessment and prompt intervention are essential in 
determining the best patient response during IABP weaning. While this should 
never change, design of a score which measures a patient’s individual cardiac 
function would seem an appropriate step to assist in the management of IABP 
minimisation and withdrawal. Importantly, a score determining cardiac 
decompensation would be beneficial regardless of the manner of IABP 
support withdrawal adopted by the clinician. As research specific to IABP 
weaning faces numerous difficulties, provision of evidence to assist weaning 
may lie in the measurement of cardiac function. The authors of this paper 
designed a ‘cardiac decompensation score’ with the purpose of accurately 
representing cardiac decompensation specific to a patient’s individual cardiac 
function.  
 
Following its initial application to practice in 1968, IABP has become the most 
widely used mechanical support in the assistance of a failing heart 
(Christenson et al., 2002). Though extensive research has been undertaken in 
this field over the past four decades very little study has directly examined the 
withdrawal of IABP support. O’Malley (2000) examined the haemodynamic 
effects of two patterns of IABP weaning and while her overall results were not 
statistically significant, they did suggest volume weaning to generate a more 
positive haemodynamic outcome for the patient. Through critical analysis and 
synthesis of numerous IABP papers, Lewis and Courtney (2006) also suggest 
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volume reduction to appear the most effective weaning method; they also 
found frequency weaning to appear problematic. Australasian IABP practice 
meanwhile, indicates frequency reduction to demonstrate the better weaning 
outcome (Lewis et al., 2006). Discussion regarding both volume and 
frequency reduction weaning as well as combinations of both methods can be 
found in numerous papers with all demonstrating apparent success (Bavin 
and Self, 1991; Bolooki, 1998; Christenson and Schmuzinger, 1999; 
Kantrowitz et al., 1993; Krau, 1999; Vitale, 1999). No empiric justification, 
however, can be found for any IABP weaning processes as all methods 
appear based around past practice, clinician preference and support 
withdrawal alternatives available on the IABP drive console. Given this, a 
score able to measure a patient’s cardiac function would seem an appropriate 
step to assist in the management of IABP weaning and could be applied in 
any acute care setting internationally. The aim of this study was to clinically 
test the ‘cardiac decompensation score’ and determine its sensitivity. To meet 
this aim this study set out to answer the research question “Can the ‘cardiac 
decompensation score’ accurately identify deterioration of cardiac function in 
a patient who is already cardiac compromised?” 
 
METHODS 
To examine the clinical efficacy of the cardiac decompensation score a quasi-
experimental, one-group posttest-only design was utilised. After obtaining the 
approval of both the hospital and university ethics committees, 23 patients 
managed consecutively with IABP consented to be enrolled in the study. Data 
were collected in Brisbane, Australia at The Prince Charles Hospital – a 450 
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bed metropolitan, government funded public, cardiothoracic tertiary referral 
teaching hospital. The study did not require any change in patient treatment – 
observations only were collected over the course of IABP and were compared 
against fluctuations in therapy to determine a patient’s cardiac function. 
Observations were collected on all patients for the duration of IABP therapy 
and were used to determine the patient’s cardiac decompensation score. To 
ensure blinding, doctors regulating patient treatments did not have access to 
the score – all scores were generated by the nurse caring for the patient. 
 
Instrument 
In attempting to predict IABP mortality following cardiac surgery, a 
retrospective Australian study undertaken at the Austin Hospital in Melbourne 
examined a number of clinical variables (Davies et al., 2001). They found 
statistically significant predictors of mortality and failure to wean from IABP to 
include: lactate; base deficit; mean arterial pressure; development of acute 
renal failure; and urine output. A recent survey of Australasian IABP 
management identified physiological criteria of importance prior to IABP 
weaning to include heart rate, blood pressure and to a moderate extent gas 
exchange (Lewis et al., 2006). While the Davies study strongly suggests the 
inclusion of lactate levels, renal function and metabolic measures in the 
cardiac decompensation score, Australasian IABP weaning practice (Lewis) 
identifies heart rate, blood pressure and lung function as worthy of inclusion. 
Despite score incorporation of these clinical variables, the extent of 
physiological changes manifested by impaired cardiac function remain 
extensive and require further consideration. Owing to an absence of evidence 
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and lack of clinical studies, other possible aspects for score inclusion 
warranted selection based upon clinical experience and physiological 
knowledge of cardiac function and homeostatic mechanisms. Homeostatic 
response heralds an initial decline in cardiac function and consequent bodily 
compensation. In addition to Davies’ lactate levels, peripheral perfusion was 
identified for score inclusion. Clinical experience also saw the addition of two 
delayed determinates of a failing heart – electrocardiograph (ECG) and 
mentation. Owing to its impact upon blood pressure, fluid replacement was 
also included (as most IABP recipients at the study centre are nil by mouth 
fluid replacement is required; this parameter was consequently weighted less 
than others).  
 
Following generation of cardiac decompensation score clinical indicators the 
authors sought consultation with an expert panel. Chosen for relevant clinical 
experience and expert knowledge the panel consisted intensivists, cardiac 
surgeons and cardiac intensive care nurses. While all 10 selected score 
components were preserved some component parameters were refined. Prior 
to data collection, the score was tested on a purposive sample of 10 nurses 
varying in age, gender and clinical experience. Inter-rater reliability was high 
(Fleiss’ kappa, κ=0.91) while participant score generation demonstrated ease 
and speed. 
 
Regardless of the underlying pathology, treatment of severe cardiac 
dysfunction requires institution and escalation of multiple supportive therapies 
until the patient condition can be stabilised. Following successful patient 
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stabilisation, the decision to minimise any supportive therapy indicates the 
optimum cardiac function which can be expected for the patient under their 
current clinical circumstance. Immediately prior to this initial therapy 
minimisation, a baseline may be generated for this patient by which to 
correlate their clinical improvement or deterioration. Using the cardiac 
decompensation score, the patient value for each score parameter is 
documented prior to the initial minimisation of any support to generate a 
baseline. Subsequent patient comparison against their own baseline rather 
than a generic range for any particular observation or measurement ensures 
the score reflects a patient’s individual cardiac function.  
 
The cardiac decompensation score incorporates 10 related aspects of cardiac 
function: heart rate; ECG; blood pressure; urine output; lactate; perfusion; 
lung function; metabolic status; mentation; and fluid replacement. With the 
exception of fluid replacement, each of the 10 parameters in the cardiac 
decompensation score were weighted equally. Scores range from a minimum 
of zero to a maximum of five (fluid replacement is allocated a maximum score 
of 2.5) (Table 1). In an attempt to maximise the sensitivity of the score, 
designated ranges were relatively small. Escalating scores reflect patient 
deterioration while scores of zero indicate condition stability or improvement. 
Following baseline generation, scores are calculated one to two hourly 
(depending upon patient stability) and upon intervention. Intervention in this 
study was defined as any change in patient treatment (escalation or reduction 
in treatment, or a combination of these). Interventions occurring in this study 
were: inotrope/vasopressor increase; simultaneous increase of two or more 
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inotropes/vasopressors; simultaneous inotrope/vasopressor increase and 
inotrope/vasopressor decrease; inotrope/vasopressor decrease; return to 
theatre; IABP frequency reduction; IABP augmentation reduction; IABP 
withdrawal; cessation of mechanical ventilation; cardiac arrest; and in the 
event of impending patient death – total treatment cessation. Some 
‘interventions’ could be classified as ‘events.’ However, the infrequency with 
which these events occurred (e.g. cardiac arrest) saw the authors liberally 
classify ‘interventions’ and ‘events’ together. Drugs classified as interventional 
in this study required continual infusion and were: adrenaline; noradrenaline; 
dopamine; dobutamine; and isoprenaline.  
Take in Table 1 here 
 
Statistical analysis and comparison 
Data were analysed using descriptive and inferential statistics. Kruskall-Wallis 
test, Wilcoxon test, one or two sample t-tests, sign tests for trend and 
estimation of autocorrelations were performed using Minitab software, version 
15. Changes in treatment were classified as increases, decreases or mixed 
changes. The obvious interest is to compare scores across these categories, 
and likewise to compare changes in score within and across these categories, 
but this raises the issue of dependent (autocorrelated) observations. In order 
to deal with this issue and carry out the desired analysis, advice was taken on 
estimating autocorrelation and adjusting for its effects in such a setting. These 
adjustments were found to be necessary for comparing scores but not for 
comparing changes in score (since autocorrelations of the changes in score 
were not statistically significant for this data set). 
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Due to the non-regularity of observation intervals, changes in scores were 
analysed by first estimating the rates of change of these scores (dividing the 
difference between successive scores by the corresponding difference 
between observation times). The rates of change were tested against a null 
hypothesis value of zero, which corresponds to a static score. Mean rates of 
change were compared against zero using t-tests while median rates of 
change were tested against zero using the Wilcoxon test. In all cases, the 
tests were conducted as two-tailed tests. 
 
RESULTS 
During the period July 3, 2003 to November 10, 2003, 23 patients (65.2% 
male) were treated with consecutive IABP at The Prince Charles Hospital. 
Median patient age was 68 years (18 to 84 years; SD 16.4) while median 
duration of device support was 45.75 hours (SD 37.7). Intensive care unit 
(ICU) mortality was 17.4% (three patients expired with the intraaortic balloon 
in place while the fourth patient expired 15 minutes following catheter 
removal). Indications for IABP were: weaning from cardiopulmonary bypass 
(30.4%); mechanical complications due to acute myocardial infarction 
(30.4%); cardiogenic shock (26.1%); and preoperative support in the high risk 
cardiac patient undergoing coronary artery bypass surgery (13.1%). Patients 
yielded 707 observations (6 to 64 observations per patient; median 29). Each 
observation (excluding the first which was used in baseline generation) 
produced a cardiac decompensation score used to establish the patient’s level 
of cardiac function. The majority of baseline observations were taken between 
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one and two hours post IABP insertion. In four cases baseline observations 
were generated four to six hours post insertion and in one case 46 hours 
following insertion. The interval between score generation was commonly one 
or two hours, although there were intervals of 15 minutes (9 times), 30 
minutes (27 times), 45 minutes (8 times), 75 minutes (three times) and 90 
minutes (twice). Combined, three of the more stable IABP recipients produced 
two 4 hour score intervals, a 5.5 hour interval, and one 21 hour interval.  
 
For this dataset the maximum cardiac decompensation score observed was 
32 and the minimum was zero. In all but two survivors the score was zero at 
the end of the observation period (one final score was 1; one final score was 9 
– this patient required treatment escalation 10 minutes later). All four non-
survivors exhibited predominantly rising scores over the observation period 
and had final scores of 25 or higher. In contrast, the maximum score obtained 
by a survivor at any time was 15 (Figure 1) and the average rate of change 
was negative (i.e., scores decreased on average). For non-survivors as a 
group, the p-values for testing mean and median rates of increase against 
zero were both <0.001, while the corresponding test for survivors did not 
reach significance.  
Take in Figure 1 here 
 
Survivors demonstrated higher median scores when their treatment was 
escalated in comparison to when their treatment remained static or was 
minimised (p<0.001 for two-sample t-test after adjusting for autocorrelation 
effects). However of greater importance, scores for all participants regardless 
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of survival demonstrate increasing average values immediately prior to a 
treatment escalation and decreasing average values immediately following 
this escalation in therapy (post change: p=0.016, for t-test; p=0.001 for 
Wilcoxon test; pre-change results indicative but not statistically significant).  
 
A comparison was also performed to examine the proportion of rising, static 
and falling scores immediately prior to, and following treatment escalation. 
Half of all scores are rising prior to an escalation and more than half of all 
scores fall after an escalation. Furthermore, a trend test for changes between 
rising, static and falling categories either side of each escalation indicates a 
trend for score changes to move from rising to falling at such events (p=0.024 
for sign test; score changes classified as rising, static or falling according to 
their algebraic sign (positive / zero / negative) (Figure 2). 
Take in Figure 2 here 
 
DISCUSSION 
In the presence of a reduced cardiac reserve, the patient’s ability to attain 
accepted norms of observations such as blood pressure and heart rate is 
impaired. In this instance, the clinician uses clinical judgement and experience 
to determine which observation range will be acceptable for this particular 
patient. Improvement in their condition, however, can be difficult to determine 
given continuous adjustment in support provided by multiple assistive 
therapies. The cardiac decompensation score was designed with the specific 
intention of accurately measuring deterioration of heart function in a cardiac 
compromised patient. Results of this study demonstrated scores to increase 
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prior to an escalation in therapy, and decrease both following treatment 
escalation and prior to therapy minimisation thus correlating with clinical 
interventions. These correlations in score fluctuations suggest the cardiac 
decompensation score to accurately identify further deterioration (or 
improvement) in a patient’s already compromised cardiac function. Further, 
while some score fluctuations coincided with an intervention, they were most 
likely to be seen prior to an intervention. An increase in score was regularly 
seen one to two hours preceding treatment escalation and as early as three 
hours preceding an escalation. Score increases preceding clinician response 
by these margins may indicate the score to reflect changes in cardiac function 
prior to clinician observation. 
 
Cardiac decompensation score appraisal 
Factors worth deliberation prior to future application of this score are heart 
rate, temperature and fluid replacement. Participants were frequently paced, 
negating the potential influence heart rate had on the score. In the instance of 
pacing it may be prudent to double the blood pressure weighting and offer a 
substitute scale with smaller increments. Temperature may commence from a 
low baseline with the return of a patient from a long stay in the operating 
theatre. A warming blanket will quickly generate a score of 1.5 for the patient. 
Alteration of the baseline temperature would be required to limit this influence 
on future scoring. Although not specifically recorded in this study, it would 
appear sensible to include blood products in the fluid replacement category 
rather than simply volume. One unit of packed cells for example, is 350 
millilitres of colloid and will fail to register a score. Lastly, to ensure optimum 
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score function, it should be considered that a patient’s baseline may need to 
be reset if their condition improves markedly. 
 
Study limitations 
Statistical limitations of this study include the small sample size and the issue 
of adjusting appropriately for autocorrelated observations. The other main 
limitation is the use of a high acuity population – mortality for those treated 
with IABP is upwards of 20% (Cohen et al., 2003; Lewis et al., 2007). 
However, while study in the setting of IABP limits generalisability, it must be 
recognised the score has been tested in a robust manner on a critically ill, 
high acuity group. It may also be argued the absence of haemodynamic data 
provided by a pulmonary artery catheter is a study limitation. Routine practice 
for The Prince Charles Hospital, however, incorporates liberal application of 
echocardiography utilised in preference to pulmonary artery catheters. At least 
30% of Australasian ICU’s don’t routinely use pulmonary artery catheters in 
the setting of IABP (Lewis et al., 2006). Further to this, only 59% of 
Australasian practitioners believe pulmonary artery wedge pressures to be of 
importance prior to the minimisation of IABP support or catheter withdrawal 
while even fewer practitioners (20%) consider cardiac index of importance 
(Lewis et al., 2006).  
 
CONCLUSION 
Difficulties arise in the treatment of a patient with cardiac failure when 
attempting to interpret their vital signs and clinical data in the presence of 
multi-modality supports. Arbitrary normal ranges may be inappropriate or 
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difficult to achieve despite implementation of multiple supportive therapies. In 
this pilot population, the cardiac decompensation score suggests its 
usefulness in identifying a patient’s individual level of cardiac function. The 
ability of this score, whether by absolute values or trends to predict patient 
outcome, warrants further investigation. 
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TABLE 1: Cardiac Decompensation Score. 
 
Parameter 
 
Score 
 
Heart rate:               ≤ 10bpm  from baseline 
 
0 
                                ≥ 11bpm  ≤ 20bpm  from baseline 1.5 
                                ≥ 21bpm  ≤ 28bpm  from baseline 3 
                                ≥ 29bpm  from baseline 5 
ECG:                       cardiac rhythm remains stable 0 
                                arrhythmia ≥ 5 seconds 2 
                                ST elevation ≥ 3 squares 3 
Blood pressure:       systolic remains static or  from baseline 0 
                                systolic  ≤ 5mmHg from baseline 0 
                                systolic  ≥ 6mmHg ≤ 10mmHg  from baseline 1 
                                systolic  ≥ 11mmHg ≤ 15mmHg from baseline 3 
                                systolic  ≥ 16mmHg from baseline 5 
Urine output:           ≥ 0.5mls/kg/hr over previous hour 0 
                                ≤ 0.49mls/kg/hr ≥ 0.26mls/kg/hr over previous hour 1 
                                ≤ 0.25mls > 0 over previous hour 2.5 
                                anuric over previous hour 5 
Lactate:                   ≤ baseline + 1.5 mmol/lt 0 
                                ≥ baseline + 1.6mmol/lt ≤ baseline + 2.5mmol/lt 1 
                                ≥ baseline + 2.6mmol/lt ≤ baseline + 6mmol/lt 2 
                                ≥ baseline + 6.1 mmol/lt 5 
Perfusion:                finger capillary refill ≤ baseline + 1 sec 0 
                                finger capillary refill ≥ baseline + 1.1 sec ≤ 2 sec 1 
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                                finger capillary refill ≥ baseline + 2.1 sec ≤ 3 sec 2.5 
                                finger capillary refill ≥ baseline + 3.1 sec 5 
Lung function:         O2 requirement  from baseline 1 
                                pulmonary oedema develops or  0.5 
                                sputum retention develops or  0.5 
                                crackles develop or  0.5 
                                chest sounds  0.5 
                                SaO2  > 5% (baring O2 change) 0.5 
                                respiratory rate  30% from baseline 1.5 
                                none of the above 0 
Metabolic status:     temperature  ≥ 1ºC from baseline 1.5 
                                pH moves ≥ 0.1 from baseline 3.5 
                                none of the above 0 
Mentation:               Glasgow Coma Scale ≥ baseline minus 1 0 
                                Glasgow Coma Scale ≤ baseline minus 2 2 
                                Glasgow Coma Scale ≤ baseline minus 3 5 
Fluid replacement:   ≤ 1lt crystalloid or 0.5 lt colloid within 3 hrs 0 
                                 > 1lt crystalloid or 0.5 lt colloid within 3 hrs 2.5 
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Figure 1: Plot of Cardiac Decompensation scores verse change in treatment. 
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FIGURE 2: Bar Graph of Cardiac Decompensation Score Changes 
Immediately Prior to, and Immediately Following Treatment Escalation. 
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